Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen

J Chemother. 2012 Aug;24(4):245-6. doi: 10.1179/1973947812Y.0000000008.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / adverse effects*
  • Adjuvants, Immunologic / therapeutic use
  • Administration, Metronomic
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma / drug therapy*
  • Carcinoma / immunology
  • Carcinoma / secondary
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / immunology
  • Deoxycytidine / therapeutic use
  • Female
  • Fluorouracil / therapeutic use
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • Humans
  • Injections, Subcutaneous
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / adverse effects*
  • Interleukin-2 / therapeutic use
  • Leucovorin / therapeutic use
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / immunology
  • Lung Neoplasms / secondary
  • Lymphatic Metastasis / immunology
  • Lymphatic Metastasis / prevention & control
  • Maintenance Chemotherapy
  • Organoplatinum Compounds / therapeutic use
  • Remission Induction
  • Sjogren's Syndrome / chemically induced*
  • Sjogren's Syndrome / immunology
  • Treatment Outcome

Substances

  • Adjuvants, Immunologic
  • IL2 protein, human
  • Interleukin-2
  • Organoplatinum Compounds
  • Deoxycytidine
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Leucovorin
  • Fluorouracil

Supplementary concepts

  • GOLF protocol